Overview
Sweden immunotherapy developer posted Q1 net loss narrowed yr/yr, with no revenue reported
Mendus drew SEK 30 mln from loan facility and issued warrants to Fenja Capital II A/S
Result Drivers
ADDITIONAL FINANCING - Co drew SEK 30 mln from loan facility and issued warrants to Fenja Capital II A/S to support operations
Company press release: ID:nMFNv3Ncv
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EPS
-SEK 0.34
Q1 Operating Profit
-SEK 20.10 mln
Analyst Coverage
Wall Street's median 12-month price target for Mendus AB (publ) is SEK15.00, about 229.3% above its May 7 closing price of SEK4.56
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
